CalciMedica, Inc. financial data

Symbol
CALC on Nasdaq
Location
505 Coast Boulevard South, Suite 307, La Jolla, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 516 % +11.2%
Debt-to-equity 98.9 % +105%
Return On Equity -207 % -111%
Return On Assets -104 % -57.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 14M shares +30%
Common Stock, Shares, Outstanding 14M shares +30%
Entity Public Float 27.9M USD +138%
Common Stock, Value, Issued 4K USD +33.3%
Weighted Average Number of Shares Outstanding, Basic 15M shares +34.7%
Weighted Average Number of Shares Outstanding, Diluted 15M shares +34.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 15.7M USD +23.7%
General and Administrative Expense 9.37M USD +6.6%
Operating Income (Loss) -25M USD -16.7%
Nonoperating Income (Expense) 4.15M USD -53.1%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -20.9M USD -65.8%
Earnings Per Share, Basic -1 USD/shares -110%
Earnings Per Share, Diluted -1 USD/shares -110%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.92M USD +17%
Cash, Cash Equivalents, and Short-term Investments 18M USD -5.76%
Assets, Current 19M USD -7.23%
Property, Plant and Equipment, Net 105K USD -23.9%
Operating Lease, Right-of-Use Asset 0 USD -100%
Assets 19.1M USD -9.37%
Accounts Payable, Current 1.91M USD -10.8%
Employee-related Liabilities, Current 758K USD -6.77%
Liabilities, Current 3.48M USD -11.2%
Liabilities 13M USD +79.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -4K USD +55.6%
Retained Earnings (Accumulated Deficit) -171M USD -13.9%
Stockholders' Equity Attributable to Parent 6.1M USD -55.9%
Liabilities and Equity 19.1M USD -9.37%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.88M USD -3.46%
Net Cash Provided by (Used in) Financing Activities 10.7M USD -43.6%
Net Cash Provided by (Used in) Investing Activities -1.24M USD +90.5%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 14M shares +30%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 4.62M USD +277%
Deferred Tax Assets, Valuation Allowance 88.5M USD +7.13%
Deferred Tax Assets, Gross 88.5M USD +7.12%
Operating Lease, Liability 117K USD -76.2%
Depreciation 58K USD -3.33%
Payments to Acquire Property, Plant, and Equipment 9K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -20.9M USD -65.7%
Lessee, Operating Lease, Liability, to be Paid 118K USD -76.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1K USD -94.1%
Deferred Tax Assets, Operating Loss Carryforwards 62.4M USD +6.62%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 11.5M USD +3.63%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 13K USD 0%
Operating Leases, Future Minimum Payments Due, Next Twelve Months 118K USD
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 12M USD +759%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%